SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q4 2023 · 65 positions · Total reported value $318.86M · Top-10 concentration 39.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q4 2023 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 65 equity positions with a combined reported value of $318.86M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 39.2% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2023 were MRUS ($17.75M), MORF ($14.44M), NUVL ($14.20M). By sector, the heaviest allocations are Health Care 67.1%, Industrials 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+10.8pp) and away from Other (-10.9pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 56% of names.

The largest new positions opened in Q4 2023 were NUVL ($14.20M), RCKT ($11.47M), MDT ($11.12M).

Of the 18 positions fully exited versus the prior quarter, the largest were XBI ($21.91M), KRYS ($8.30M), CRNX ($6.54M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2023)

  • NUVL NUVALENT INC · $14.20M
  • RCKT ROCKET PHARMACEUTICALS INC · $11.47M
  • MDT MEDTRONIC PLC · $11.12M
  • SNY SANOFI · $10.94M
  • CLDX CELLDEX THERAPEUTICS INC NEW · $9.80M
  • ALPN ALPINE IMMUNE SCIENCES INC · $5.68M
  • ISRG INTUITIVE SURGICAL INC · $5.33M
  • PEN PENUMBRA INC · $5.03M

Fully Exited (vs previous quarter)

  • XBI SPDR SERIES TRUST · prev qtr: $21.91M
  • KRYS KRYSTAL BIOTECH INC · prev qtr: $8.30M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $6.54M
  • NVO NOVO-NORDISK A S · prev qtr: $5.46M
  • HUM HUMANA INC · prev qtr: $4.87M
  • VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $4.79M
  • GILD GILEAD SCIENCES INC · prev qtr: $4.71M
  • IMGN IMMUNOGEN INC · prev qtr: $3.97M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 67.1%
Other 32.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 645.58K $17.75M 5.57%
5.57%
Add
2 500.04K $14.44M 4.53%
4.53%
Reduce
3 193.00K $14.20M 4.45%
4.45%
New
4 3.71M $12.45M 3.90%
3.90%
Add
5 1.26M $12.11M 3.80%
3.80%
Hold
6 382.67K $11.47M 3.60%
3.60%
New
7 135.00K $11.12M 3.49%
3.49%
New
8 220.00K $10.94M 3.43%
3.43%
New
9 1.17M $10.76M 3.38%
3.38%
Add
10 247.22K $9.80M 3.08%
3.08%
New
11 150.00K $8.81M 2.76%
2.76%
Hold
12 573.83K $8.05M 2.52%
2.52%
Add
13 174.25K $8.01M 2.51%
2.51%
Reduce
14 525.40K $7.88M 2.47%
2.47%
Add
15 163.17K $7.52M 2.36%
2.36%
Add
16 247.72K $6.81M 2.14%
2.14%
Add
17 283.84K $6.32M 1.98%
1.98%
Reduce
18 249.25K $5.82M 1.82%
1.82%
Add
19 318.52K $5.77M 1.81%
1.81%
Add
20 80.00K $5.73M 1.80%
1.80%
Reduce
21 966.75K $5.68M 1.78%
1.78%
Add
22 297.79K $5.68M 1.78%
1.78%
New
23 6.13M $5.59M 1.75%
1.75%
Hold
24 15.81K $5.33M 1.67%
1.67%
New
25 795.08K $5.26M 1.65%
1.65%
Add
26 20.00K $5.18M 1.62%
1.62%
Reduce
27 218.97K $5.17M 1.62%
1.62%
Add
28 900.82K $5.16M 1.62%
1.62%
Add
29 270.00K $5.08M 1.59%
1.59%
Add
30 20.00K $5.03M 1.58%
1.58%
New
31 155.50K $4.82M 1.51%
1.51%
Add
32 46.88K $4.52M 1.42%
1.42%
Add
33 31.00K $3.85M 1.21%
1.21%
New
34 594.86K $3.65M 1.15%
1.15%
New
35 16.36K $3.60M 1.13%
1.13%
Reduce
36 517.00K $3.36M 1.05%
1.05%
Add
37 1.50M $3.24M 1.02%
1.02%
Add
38 1.00M $3.04M 0.95%
0.95%
Reduce
39 70.69K $3.03M 0.95%
0.95%
Add
40 50.00K $3.02M 0.95%
0.95%
New
41 73.67K $2.97M 0.93%
0.93%
Reduce
42 3.10M $2.60M 0.82%
0.82%
Hold
43 80.81K $2.39M 0.75%
0.75%
Reduce
44 463.00K $2.16M 0.68%
0.68%
Add
45 417.43K $1.90M 0.59%
0.59%
Add
46 940.00K $1.86M 0.58%
0.58%
Add
47 4.83K $1.84M 0.58%
0.58%
New
48 158.72K $1.77M 0.56%
0.56%
Add
49 550.00K $1.71M 0.54%
0.54%
New
50 150.00K $1.69M 0.53%
0.53%
New

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2023-Q4?

In its 2023-Q4 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 65 equity positions worth $318.86M in aggregate; its largest disclosed positions were MRUS ($17.75M), MORF ($14.44M), NUVL ($14.20M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $318.86M of long equity holdings across 65 positions as of 2023-Q4. Top-10 holdings account for 39.2% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →